Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Eli Lilly and Company    LLY

ELI LILLY AND COMPANY (LLY)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Lilly buys Siga's Priority Review voucher gained via smallpox approval

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/01/2018 | 09:11am EST

Eli Lilly and Co. (NYSE:LLY) acquired a Priority Review voucher from Siga Technologies Inc. (NASDAQ:SIGA) for $80 million. The voucher, which Siga obtained in July upon approval of TPOXX tecovirimat to treat smallpox, was the first FDA awarded under its Material Threat Medical Countermeasure voucher program.

TPOXX, an oral small molecule antiviral, is the first drug FDA has approved to treat smallpox (see "Siga Gets Priority Review Voucher For First Approved Smallpox Drug").

Priority Review voucher prices have ranged from $67.5 million to $350 million since the first one was issued in 2009. Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) and Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) sold one in July for $80.6 million (see "Voucher Equilibrium" and "Kyowa, Ultragenyx Sell Priority Review Voucher For $80.6M").

The medical countermeasure program was created under the 21st Century Cures Act, and awards vouchers for "medical products intended to diagnose, prevent or treat diseases or conditions associated with threats and emerging infectious diseases."

Siga was up $0.27 to $5.10 in early trading Thursday.

.

(C) 2018 M2 COMMUNICATIONS, source M2 PressWIRE

Stocks mentioned in the article
ChangeLast1st jan.
ELI LILLY AND COMPANY -2.16% 116.59 Delayed Quote.2.97%
KIRIN HOLDINGS CO LTD 1.52% 2500 End-of-day quote.10.94%
KYOWA HAKKO KIRIN CO LTD 0.05% 2116 End-of-day quote.4.39%
SIGA TECHNOLOGIES, INC. -0.81% 7.34 Delayed Quote.-7.09%
ULTRAGENYX PHARMACEUTICAL INC 3.47% 53.34 Delayed Quote.22.68%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ELI LILLY AND COMPANY
01/18ELI LILLY AND : Lilly Reports Favorable Cyramza Results in Phase 3 Liver Cancer ..
DJ
01/18MARKET SNAPSHOT: Stocks Close Higher For Fourth Day As Optimism Mounts Over U..
DJ
01/18ELI LILLY AND : Sarcoma Drug Combo Proves Ineffective in Trials--Update
DJ
01/18ELI LILLY AND : Lartruvo fails confirmatory study; Lilly suspending promotion
AQ
01/18ELI LILLY AND : Sarcoma Drug Combo Proves Ineffective in Trials
DJ
01/18ELI LILLY AND : Lilly Reports Results of Phase 3 Soft Tissue Sarcoma Study of LA..
PU
01/16ELI LILLY AND : Help for People, Including Federal Employees
PU
01/08WEISSLAW LLP : Loxo Oncology, Inc. Acquisition May Not Be In The Best Interests ..
PR
01/08GlaxoSmithKline to look for early-stage assets - CEO
RE
01/08ELI LILLY AND : to cut 250 jobs at France plant, through voluntary redundancy
RE
More news
Financials ($)
Sales 2018 24 420 M
EBIT 2018 6 756 M
Net income 2018 3 254 M
Debt 2018 4 468 M
Yield 2018 1,92%
P/E ratio 2018 37,80
P/E ratio 2019 21,91
EV / Sales 2018 5,35x
EV / Sales 2019 5,14x
Capitalization 126 B
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Average target price 118 $
Spread / Average Target -1,1%
EPS Revisions
Managers
NameTitle
David A. Ricks Chairman, President & Chief Executive Officer
Thomas F. Bumol Senior VP-Biotechnology & Autoimmunity Research
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Michael R. Meadows VP & Chief Technology Officer
Aarti Shah Chief Information Officer & SVP-IT
Sector and Competitors
1st jan.Capitalization (M$)
ELI LILLY AND COMPANY2.97%126 229
JOHNSON & JOHNSON0.03%350 508
PFIZER-2.70%246 674
NOVARTIS5.66%227 840
ROCHE HOLDING LTD.6.16%223 498
MERCK AND COMPANY-0.71%197 291